Richard S
Future Oncol. 2024; 20(39):3313-3324.
PMID: 39513232
PMC: 11633412.
DOI: 10.1080/14796694.2024.2420629.
Lu H, Wang Y, Chaudhary S, Balaga V, Ke H, Shi F
Am J Pathol. 2024; 194(11):2007-2022.
PMID: 39168365
PMC: 11816638.
DOI: 10.1016/j.ajpath.2024.07.018.
Liu S, Zang Y, Huang C, Liu Y
Cancer Rep (Hoboken). 2023; 7(1):e1921.
PMID: 37884351
PMC: 10809273.
DOI: 10.1002/cnr2.1921.
Fahmy S, Dawoud A, Zeinelabdeen Y, Kiriacos C, Daniel K, Eltahtawy O
Cancers (Basel). 2022; 14(21).
PMID: 36358663
PMC: 9657918.
DOI: 10.3390/cancers14215244.
Mohammed O, Cebrero M, Ahmad O, Peet A, Grundy R, Lourdusamy A
Cancers (Basel). 2022; 14(1).
PMID: 35008416
PMC: 8750554.
DOI: 10.3390/cancers14010251.
Notch signaling and natural killer cell infiltration in tumor tissues underlie medulloblastoma prognosis.
Liang K, Chang C, Wu K, Yu A, Sung S, Lee Y
Sci Rep. 2021; 11(1):23282.
PMID: 34857809
PMC: 8639846.
DOI: 10.1038/s41598-021-02651-y.
Medulloblastoma: novel insights into emerging therapeutic targets.
Shaik S, Maegawa S, Gopalakrishnan V
Expert Opin Ther Targets. 2021; 25(8):615-619.
PMID: 34602009
PMC: 8552961.
DOI: 10.1080/14728222.2021.1982896.
Bioinformatics Analysis of Key Genes and Pathways for Medulloblastoma as a Therapeutic Target.
Aghamaleki F, Mollashahi B, Aghamohammadi N, Rostami N, Mazloumi Z, Mirzaei H
Asian Pac J Cancer Prev. 2019; 20(1):221-227.
PMID: 30678435
PMC: 6485566.
DOI: 10.31557/APJCP.2019.20.1.221.
Molecular characterization of Wnt pathway and function of β-catenin overexpression in medulloblastoma cell lines.
Geron L, Salomao K, Borges K, Andrade A, Correa C, Scrideli C
Cytotechnology. 2018; 70(6):1713-1722.
PMID: 30374857
PMC: 6269366.
DOI: 10.1007/s10616-018-0260-2.
SPARC overexpression alters microRNA expression profiles involved in tumor progression.
Ahir B, Elias N, Lakka S
Genes Cancer. 2017; 8(1-2):453-471.
PMID: 28435518
PMC: 5396623.
DOI: 10.18632/genesandcancer.130.
IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.
Folgiero V, Miele E, Carai A, Ferretti E, Alfano V, Po A
Oncotarget. 2016; 7(33):52900-52911.
PMID: 27174915
PMC: 5288157.
DOI: 10.18632/oncotarget.9284.
Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines.
Zomerman W, Plasschaert S, Diks S, Lourens H, Boer T, Hoving E
PLoS One. 2015; 10(10):e0141381.
PMID: 26496080
PMC: 4619778.
DOI: 10.1371/journal.pone.0141381.
The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.
Vriend J, Ghavami S, Marzban H
Mol Brain. 2015; 8(1):64.
PMID: 26475605
PMC: 4609148.
DOI: 10.1186/s13041-015-0155-5.
Na,K-ATPase β1-subunit is a target of sonic hedgehog signaling and enhances medulloblastoma tumorigenicity.
Lee S, Litan A, Li Z, Graves B, Lindsey S, Barwe S
Mol Cancer. 2015; 14:159.
PMID: 26286140
PMC: 4544806.
DOI: 10.1186/s12943-015-0430-1.
XAV939-mediated ARTD activity inhibition in human MB cell lines.
Renna C, Salaroli R, Cocchi C, Cenacchi G
PLoS One. 2015; 10(4):e0124149.
PMID: 25835728
PMC: 4383513.
DOI: 10.1371/journal.pone.0124149.
Zebrafish reporter lines reveal in vivo signaling pathway activities involved in pancreatic cancer.
Schiavone M, Rampazzo E, Casari A, Battilana G, Persano L, Moro E
Dis Model Mech. 2014; 7(7):883-94.
PMID: 24878567
PMC: 4073277.
DOI: 10.1242/dmm.014969.
SHH, WNT, and NOTCH pathways in medulloblastoma: when cancer stem cells maintain self-renewal and differentiation properties.
Mascaro Cordeiro B, Oliveira I, Alves M, Saba-Silva N, Capellano A, Cavalheiro S
Childs Nerv Syst. 2014; 30(7):1165-72.
PMID: 24695855
DOI: 10.1007/s00381-014-2403-x.
G-quadruplexes as potential therapeutic targets for embryonal tumors.
Shalaby T, Fiaschetti G, Nagasawa K, Shin-Ya K, Baumgartner M, Grotzer M
Molecules. 2013; 18(10):12500-37.
PMID: 24152672
PMC: 6269990.
DOI: 10.3390/molecules181012500.
A contemporary review of molecular candidates for the development and treatment of childhood medulloblastoma.
Sumer-Turanligil N, Cetin E, Uyanikgil Y
Childs Nerv Syst. 2013; 29(3):381-8.
PMID: 23292496
DOI: 10.1007/s00381-012-2014-3.
REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski I, MacDonald T
Mol Cancer Ther. 2012; 11(8):1713-1723.
PMID: 22848092
PMC: 3763747.
DOI: 10.1158/1535-7163.MCT-11-0990.